The CRISTAL Index: Developing a combined response index for scleroderma trials assessing limited cutaneous systemic sclerosis
Scleroderma & Raynaud's UK
University of Michigan Health System
The project will establish a CRISTAL index which is defined as a combined response index for limited scleroderma, consisting of outcome measures and factors such as gut involvement, quality of life and Raynaud's. The purpose of the CRISTAL index is to create a tool of simultaneous parameters to better understand the effect of a drug to treat limited scleroderma
6.9 Resources and infrastructure (evaluation of treatments)